These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31942462)

  • 1. Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study.
    Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park JY; Shin TY; Kim JH
    Investig Clin Urol; 2020 Jan; 61(1):42-50. PubMed ID: 31942462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy.
    Chiu PK; Lai FM; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
    Ann Surg Oncol; 2016 Aug; 23(8):2707-14. PubMed ID: 26965697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
    Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M
    Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
    Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS
    J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer.
    Novak V; Vesely S; Luksanová H; Prusa R; Capoun O; Fiala V; Dolejsová O; Sedlacková H; Kucera R; Stejskal J; Zalesky M; Babjuk M
    BMC Urol; 2020 Sep; 20(1):144. PubMed ID: 32894109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy.
    Mearini L; Nunzi E; Ferri C; Bellezza G; Lolli C; Porrozzi C; Porena M
    Urol Int; 2015; 95(4):390-9. PubMed ID: 25792149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
    Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
    Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
    BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
    Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D
    Prostate; 2024 Sep; 84(12):1157-1164. PubMed ID: 38798011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
    Vukovic I; Djordjevic D; Bojanic N; Babic U; Soldatovic I
    Int Braz J Urol; 2017; 43(1):48-56. PubMed ID: 28124526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
    BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
    Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
    Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy.
    Cheng YT; Huang CY; Chen CH; Chiu ST; Hong JH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Chiang IN; Hung SC; Chiang CH
    Sci Rep; 2020 Jan; 10(1):776. PubMed ID: 31964956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
    Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
    Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
    Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.
    Abrate A; Lazzeri M; Lughezzani G; Buffi N; Bini V; Haese A; de la Taille A; McNicholas T; Redorta JP; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Freschi M; Guazzoni G
    BJU Int; 2015 Apr; 115(4):537-45. PubMed ID: 25130593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.